
“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MREO | Mereo Biopharma Group Plc | 0.31 | -1.48 | -82.75% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.31 | -82.75% |

“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027

Mereo BioPharma Group ($MREO), the London-based clinical-stage biopharmaceutical company behind the osteogenesis imperfecta candidate setrusumab, is at the center of a securities fraud lawsuit now facing a motion to dismiss

JPMorgan analyst Priyanka Grover last night downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target The firm sees regulatory uncertainty for the setrusumab program and additional uncertainty

An announcement from Mereo Biopharma Group Plc ( ($MREO) ) is now available. Mereo BioPharma Group plc is a biopharmaceutical company focused on developing and commercializing therapeutic products, with its

JPMorgan downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

The latest announcement is out from Mereo Biopharma Group Plc ( ($MREO) ). On August 11, 2026, Mereo BioPharma entered into an option and license agreement granting Sentynl Therapeutics U.S.

“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program and for the Company as a whole. We are now working together

Mereo BioPharma (MREO) and Sentynl Therapeutics, a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, have entered into an option and license agreement for the U.S. commercial and global

Mereo Biopharma (MREO) is scheduled to report 1st quarter earnings on 05/20/2026, before the market opens. Regarding Q1 estimates, Wall Street analysts expect Mereo Biopharma to post earnings of -$0.01

Mereo Biopharma Group Plc ( ($MREO) ) has shared an update. On May 14, 2026, Mereo BioPharma Group plc held its 2026 Annual General Meeting, at which all proposed resolutions
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 31, 2027TBA | $49.10M | $-0.02 | $0.00 | 0.12 | -1.72 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.